Rhumbline Advisers Has $13.10 Million Stake in Option Care Health, Inc. (NASDAQ:OPCH)

Rhumbline Advisers increased its holdings in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 3.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 564,518 shares of the company’s stock after purchasing an additional 18,237 shares during the quarter. Rhumbline Advisers’ holdings in Option Care Health were worth $13,097,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in OPCH. UMB Bank n.a. lifted its stake in Option Care Health by 41.7% in the fourth quarter. UMB Bank n.a. now owns 1,176 shares of the company’s stock valued at $27,000 after acquiring an additional 346 shares during the last quarter. International Assets Investment Management LLC lifted its stake in Option Care Health by 3,029.7% in the third quarter. International Assets Investment Management LLC now owns 2,848 shares of the company’s stock valued at $91,000 after acquiring an additional 2,757 shares during the last quarter. Quarry LP lifted its stake in Option Care Health by 327.7% in the third quarter. Quarry LP now owns 3,430 shares of the company’s stock valued at $107,000 after acquiring an additional 2,628 shares during the last quarter. Blue Trust Inc. lifted its stake in Option Care Health by 16.9% in the fourth quarter. Blue Trust Inc. now owns 4,703 shares of the company’s stock valued at $109,000 after acquiring an additional 681 shares during the last quarter. Finally, KBC Group NV lifted its stake in Option Care Health by 16.2% in the third quarter. KBC Group NV now owns 5,013 shares of the company’s stock valued at $157,000 after acquiring an additional 700 shares during the last quarter. Institutional investors and hedge funds own 98.05% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Barrington Research increased their price objective on shares of Option Care Health from $32.00 to $33.00 and gave the company an “outperform” rating in a research report on Tuesday, January 14th. Truist Financial decreased their target price on shares of Option Care Health from $41.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, November 1st. The Goldman Sachs Group lowered shares of Option Care Health from a “buy” rating to a “neutral” rating and decreased their target price for the company from $38.00 to $27.00 in a report on Monday, November 4th. JMP Securities restated a “market outperform” rating and issued a $30.00 price target (down from $31.00) on shares of Option Care Health in a research note on Friday, January 10th. Finally, UBS Group initiated coverage on shares of Option Care Health in a research note on Thursday, December 5th. They issued a “neutral” rating and a $26.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Option Care Health has a consensus rating of “Moderate Buy” and an average target price of $32.25.

Option Care Health Price Performance

OPCH opened at $32.00 on Friday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.32 and a current ratio of 1.73. The firm has a market cap of $5.45 billion, a P/E ratio of 26.89, a PEG ratio of 2.30 and a beta of 1.35. Option Care Health, Inc. has a fifty-two week low of $21.39 and a fifty-two week high of $34.63. The firm has a 50-day moving average of $27.71 and a 200 day moving average of $27.98.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.